Chidamide treatment for returning or hard-to-treat lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have lymphoma confirmed by pathology as diffuse large B-cell lymphoma
- Your lymphoma has come back (relapsed) or did not respond to at least one whole-body treatment
- You have at least one measurable tumor spot (for example, a lymph node at least 1.5 cm, or another spot over 1 cm)
- If you can become pregnant, your blood pregnancy test must be negative
- You can understand the study and sign consent willingly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.